NORTHWESTERN MEDICINE NEUROLOGY AND NEUROSURGERY PRESENTATIONS AT SNO 2022
|
Review Course - Management of High Grade Glioma
Review speaker Wednesday, November 16 11:00 – 11:35 am ET Concurrent Session: Challenges With Surgical Window of Opportunity and Phase 0 Trials in Neuro-Oncology Panelist Friday, November 18 12:05 – 12:15 pm ET BIOM-05 – The HER2 Flip: HER2 Amplification of Tumor Cells in the Cerebrospinal Fluid (CSF-TCs) of Patients With Solid Tumor Leptomeningeal Metastasis Poster presenter Friday, November 18 7:30 – 9:30 pm ET TBD Concurrent Session: Challenges With Incorporating Less-invasive Biomarkers Into Clinical Practice Presenter Saturday, November 19 7:40 – 8:00 am ET Concurrent Session: Challenges with Incorporating Less-invasive Biomarkers into Clinical Practice Panelist Saturday, November 19 8:40 – 8:45 am ET The Nuts and Bolts of Successfully Bridging Bench to Bedside Concurrent Session: The Clinician and the Basic Scientist Presenter Saturday, November 19 11:45 am – 12:05 pm ET Concurrent Session: The Clinician and the Basic Scientist Panelist Saturday, November 19 12:05 – 12:15 pm ET DDEL-01 – Animal Studies With a New CNS Drug Delivery Device to Effectively Treat Leptomeningeal Carcinomatosis Patients Abstract Session: Brain Metastases Presenter Saturday, November 19 1:45 – 1:50 pm ET |
|
Review Course - Management of Meningioma, Primary CNS Lymphoma and Rare CNS Tumors
Review speaker Wednesday, November 16 1:25 – 2:00 pm ET Clinical Considerations for Certain Patients With Von Hippel-Lindau (VHL) Disease Presenter Friday, November 18 12:45 – 2:15 pm ET SNO International Outreach Committee Lunch Panelist Saturday, November 19 12:45 – 2:15 pm ET |
|
Role of dNTP Metabolism in Mounting Post-Therapy DNA Damage Response
Concurrent Session: Modulators of Radiation Response in Brain Tumors Presenter Friday, November 18 4:55 – 5:15 pm ET Concurrent Session: Modulators of Radiation Response in Brain Tumors Panelist Friday, November 18 5:35 – 5:45 pm ET |
|
QOL-06 – Predicting Venous Thromboembolism in Patients With Adult-Type Diffuse Gliomas
Rapid Report - Session 2 Presenter Friday, November 18 8:20 – 8:25 pm ET QOL-06 – Predicting Venous Thromboembolism in Patients With Adult-Type Diffuse Gliomas Poster presenter Friday, November 18 7:30 – 9:30 pm ET |
|
CTNI-19 – A Two-part, Phase 1 Study of Rhenium-186 NanoLiposome (186RNL) Delivered by Convection Enhanced Delivery (CED) for Recurrent or Progressive Childhood Ependymoma and High-Grade Glioma (HGG)
Poster presenter Friday, November 18 7:30 – 9:30 pm ET |
|
IMMU-06 – Reduction of CD4+ T Cells Negatively Affects Survival in Old But Not Young Mice With Glioblastoma
Poster presenter Friday, November 18 7:30 – 9:30 pm ET |
|
CTNI-37 – Repeated Opening of the Blood-Brain Barrier With the Skull-Implantable SonoCloud-9 (SC9) Device: Phase 1 Trial of Nab-Paclitaxel and SC9 in Recurrent Clioblastoma
Abstract Session: Clinical Trials II Presenter Saturday, November 19 10:45 – 10:55 am ET |
DRIVING BREAKTHROUGHS IN RESEARCH AND TREATMENT OF RARE AND COMPLEX BRAIN TUMORS
|
The Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute of Robert H. Lurie Comprehensive Cancer Center offers comprehensive, leading-edge care for patients with primary or metastatic tumors of the brain or spine. Our scientists have pioneered therapies and developed better standards of care. Supported by almost $60M in research funding, we offer one of the largest portfolios of brain tumor clinical trials in the U.S., and are one of six centers in the nation with a brain tumor SPORE.
|